United Therapeutics Co. (NASDAQ:UTHR) – Analysts at Jefferies Financial Group boosted their FY2021 earnings estimates for United Therapeutics in a research report issued to clients and investors on Thursday, June 25th. Jefferies Financial Group analyst E. Yang now expects that the biotechnology company will earn $11.86 per share for the year, up from their previous forecast of $11.77. Jefferies Financial Group has a “Buy” rating and a $123.00 price objective on the stock. Jefferies Financial Group also issued estimates for United Therapeutics’ FY2022 earnings at $14.15 EPS, FY2023 earnings at $17.20 EPS and FY2024 earnings at $20.80 EPS.
United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.43 by $0.69. United Therapeutics had a net margin of 36.59% and a return on equity of 19.19%. The company had revenue of $356.30 million during the quarter, compared to analyst estimates of $343.68 million. During the same period in the prior year, the firm posted $3.58 EPS. The firm’s quarterly revenue was down 1.7% compared to the same quarter last year.
Other analysts also recently issued reports about the company. BidaskClub upgraded United Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, June 24th. Cowen restated a “buy” rating and issued a $145.00 price target on shares of United Therapeutics in a research report on Friday, June 12th. Wedbush restated a “buy” rating and issued a $243.00 price target on shares of United Therapeutics in a research report on Thursday, June 25th. Oppenheimer began coverage on United Therapeutics in a research report on Wednesday, June 24th. They set a “buy” rating and a $155.00 target price for the company. Finally, ValuEngine upgraded United Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 25th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $137.00.
UTHR stock opened at $121.00 on Monday. The firm has a fifty day moving average price of $118.93 and a 200 day moving average price of $102.15. United Therapeutics has a fifty-two week low of $74.31 and a fifty-two week high of $127.79. The company has a debt-to-equity ratio of 0.27, a quick ratio of 8.46 and a current ratio of 8.91. The firm has a market cap of $5.27 billion, a PE ratio of 10.09 and a beta of 0.87.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC grew its stake in United Therapeutics by 10.3% in the fourth quarter. Renaissance Technologies LLC now owns 3,544,433 shares of the biotechnology company’s stock valued at $312,194,000 after purchasing an additional 332,155 shares during the last quarter. State Street Corp grew its stake in United Therapeutics by 1.1% in the first quarter. State Street Corp now owns 1,916,532 shares of the biotechnology company’s stock valued at $181,735,000 after purchasing an additional 21,707 shares during the last quarter. AQR Capital Management LLC grew its stake in United Therapeutics by 30.3% in the first quarter. AQR Capital Management LLC now owns 874,306 shares of the biotechnology company’s stock valued at $82,906,000 after purchasing an additional 203,177 shares during the last quarter. Nuveen Asset Management LLC grew its stake in United Therapeutics by 48.9% in the first quarter. Nuveen Asset Management LLC now owns 776,413 shares of the biotechnology company’s stock valued at $73,624,000 after purchasing an additional 255,101 shares during the last quarter. Finally, APG Asset Management N.V. purchased a new stake in shares of United Therapeutics during the first quarter worth about $80,654,000. Institutional investors own 98.11% of the company’s stock.
In other news, Director Richard Giltner sold 5,000 shares of the firm’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $99.00, for a total transaction of $495,000.00. Following the transaction, the director now owns 8,750 shares in the company, valued at $866,250. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Tommy G. Thompson sold 3,100 shares of United Therapeutics stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $112.56, for a total value of $348,936.00. Following the completion of the transaction, the director now owns 9,050 shares in the company, valued at approximately $1,018,668. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 212,210 shares of company stock worth $25,084,232. Insiders own 10.90% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Featured Story: What are momentum indicators and what do they show?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.